{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T07:33:37Z","timestamp":1766561617513},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,19]]},"DOI":"10.7759\/cureus.36351","type":"journal-article","created":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T11:49:38Z","timestamp":1679226578000},"source":"Crossref","is-referenced-by-count":2,"title":["Oxymetazoline Hydrochloride Eye-Drops as Treatment for Myasthenia Gravis-Related Ptosis: A Description of Two Cases"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Morren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2010.496695","article-title":"Blepharoptosis","volume":"25","author":"de Figueiredo AR","year":"2010","unstructured":"de Figueiredo AR. Blepharoptosis. Semin Ophthalmol. 2010, 25:39-51. 10.3109\/08820538.2010.496695","journal-title":"Semin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob D","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987, 505:472-99. 10.1111\/j.1749-6632.1987.tb51317.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks TM","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019, 205:99-105. 10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2840","article-title":"Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta-analysis","volume":"13","author":"Nadali J","year":"2023","unstructured":"Nadali J, Ghavampour N, Beiranvand F, et al.. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta-analysis. Brain Behav. 2023, 13:e2840. 10.1002\/brb3.2840","journal-title":"Brain Behav"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar M","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB, et al.. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016, 53:363-9. 10.1002\/mus.24769","journal-title":"Muscle Nerve"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali MJ","year":"2008","unstructured":"Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008, 71:1335-41. 10.1212\/01.wnl.0000327669.75695.38","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith MJ","year":"2005","unstructured":"Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005, 89:1330-4. 10.1136\/bjo.2004.063404","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe GI","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al.. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016, 375:511-22. 10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.36.3.405","article-title":"Species-specific pharmacological properties of human alpha(2A)-adrenoceptors","volume":"36","author":"Molderings GJ","year":"2000","unstructured":"Molderings GJ, B\u00f6nisch H, Br\u00fcss M, Likungu J, G\u00f6thert M. Species-specific pharmacological properties of human alpha(2A)-adrenoceptors. Hypertension. 2000, 36:405-10. 10.1161\/01.hyp.36.3.405","journal-title":"Hypertension"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001800","article-title":"Case report: Treatment of myasthenic ptosis with topical ocular oxymetazoline","volume":"98","author":"Cooper J","year":"2021","unstructured":"Cooper J, Yang D. Case report: Treatment of myasthenic ptosis with topical ocular oxymetazoline. Optom Vis Sci. 2021, 98:1317-20. 10.1097\/OPX.0000000000001800","journal-title":"Optom Vis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.037","article-title":"Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis","volume":"127","author":"Baroody FM","year":"2011","unstructured":"Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2011, 127:927-34. 10.1016\/j.jaci.2011.01.037","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100065","article-title":"Combinations of pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: two randomized Phase 2 studies","volume":"1","author":"Price FW Jr","year":"2021","unstructured":"Price FW Jr, Hom M, Moshirfar M, et al.. Combinations of pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: two randomized Phase 2 studies. Ophthalmol Sci. 2021, 1:100065. 10.1016\/j.xops.2021.100065","journal-title":"Ophthalmol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1997.13.363","article-title":"Efficacy of oxymetazoline eye drops in non-infectious conjunctivitis, the most common cause of acute red eyes","volume":"13","author":"Xuan B","year":"1997","unstructured":"Xuan B, Chiou GC. Efficacy of oxymetazoline eye drops in non-infectious conjunctivitis, the most common cause of acute red eyes. J Ocul Pharmacol Ther. 1997, 13:363-7. 10.1089\/jop.1997.13.363","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3812","article-title":"Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials","volume":"138","author":"Slonim CB","year":"2020","unstructured":"Slonim CB, Foster S, Jaros M, Kannarr SR, Korenfeld MS, Smyth-Medina R, Wirta DL. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020, 138:1168-75. 10.1001\/jamaophthalmol.2020.3812","journal-title":"JAMA Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5070\/D306g8w0mc","article-title":"The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face","volume":"11","author":"Scheinfeld N","year":"2005","unstructured":"Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatology. 2005, 11:10.5070\/D306g8w0mc","journal-title":"Dermatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506030-00001","article-title":"Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures","volume":"6","author":"Wollina U","year":"2005","unstructured":"Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005, 6:141-50. 10.2165\/00128071-200506030-00001","journal-title":"Am J Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2004.06.006","article-title":"Efferent and afferent innervations of Mueller's muscle related to involuntary contraction of the levator muscle: important for avoiding injury during eyelid surgery","volume":"58","author":"Yuzuriha S","year":"2005","unstructured":"Yuzuriha S, Matsuo K, Ishigaki Y, Kikuchi N, Kawagishi K, Moriizumi T. Efferent and afferent innervations of Mueller's muscle related to involuntary contraction of the levator muscle: important for avoiding injury during eyelid surgery. Br J Plast Surg. 2005, 58:42-52. 10.1016\/j.bjps.2004.06.006","journal-title":"Br J Plast Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.06.013","article-title":"Peripheral branching of levator superioris muscle and M\u00fcller muscle origin","volume":"148","author":"Kakizaki H","year":"2009","unstructured":"Kakizaki H, Prabhakaran V, Pradeep T, Malhotra R, Selva D. Peripheral branching of levator superioris muscle and M\u00fcller muscle origin. Am J Ophthalmol. 2009, 148:800-3. 10.1016\/j.ajo.2009.06.013","journal-title":"Am J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/140781-oxymetazoline-hydrochloride-eye-drops-as-treatment-for-myasthenia-gravis-related-ptosis-a-description-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:13Z","timestamp":1707508693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/140781-oxymetazoline-hydrochloride-eye-drops-as-treatment-for-myasthenia-gravis-related-ptosis-a-description-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.36351","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,19]]}}}